Novavax jumps 22% as Sanofi advances Nuvaxovid for fall vaccinations, outpacing Moderna and BioNTech.

Novavax shares surged 22% following Sanofi's rollout of the Nuvaxovid COVID-19 vaccine for the fall season, giving Novavax a commercial boost through its licensing deal. Unlike Moderna and BioNTech, Novavax earns royalties from Sanofi's sales rather than direct revenue, which limits risk and reward. Moderna rose 8% on cancer pipeline news, while BioNTech saw minimal gains. The key factor going forward is how much royalty revenue Novavax will receive as Sanofi expands vaccine distribution in the U.S. and abroad.

Novavax shares jumped nearly 20% on Pluang as of Oct 06, 2026 02:11 WIB, reflecting strong buying interest with 90% of orders to buy. This contrasts with Sanofi, which edged down 0.61% despite its key role in vaccine distribution. Moderna trades near its 52-week high at USD 203.20, up almost 7%, while BioNTech shows modest gains at USD 98.13, well below its 52-week peak of USD 119.34.